1. Home
  2. VRTX vs AON Comparison

VRTX vs AON Comparison

Compare VRTX & AON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • AON
  • Stock Information
  • Founded
  • VRTX 1989
  • AON 1919
  • Country
  • VRTX United States
  • AON Ireland
  • Employees
  • VRTX N/A
  • AON N/A
  • Industry
  • VRTX EDP Services
  • AON Specialty Insurers
  • Sector
  • VRTX Technology
  • AON Finance
  • Exchange
  • VRTX Nasdaq
  • AON Nasdaq
  • Market Cap
  • VRTX 104.8B
  • AON 86.1B
  • IPO Year
  • VRTX 1991
  • AON N/A
  • Fundamental
  • Price
  • VRTX $484.74
  • AON $398.89
  • Analyst Decision
  • VRTX Buy
  • AON Hold
  • Analyst Count
  • VRTX 25
  • AON 14
  • Target Price
  • VRTX $508.09
  • AON $377.86
  • AVG Volume (30 Days)
  • VRTX 1.4M
  • AON 1.2M
  • Earning Date
  • VRTX 05-05-2025
  • AON 04-25-2025
  • Dividend Yield
  • VRTX N/A
  • AON 0.68%
  • EPS Growth
  • VRTX N/A
  • AON N/A
  • EPS
  • VRTX N/A
  • AON 12.49
  • Revenue
  • VRTX $11,020,100,000.00
  • AON $15,698,000,000.00
  • Revenue This Year
  • VRTX $10.65
  • AON $11.53
  • Revenue Next Year
  • VRTX $9.02
  • AON $6.31
  • P/E Ratio
  • VRTX N/A
  • AON $31.94
  • Revenue Growth
  • VRTX 11.66
  • AON 17.36
  • 52 Week Low
  • VRTX $377.85
  • AON $268.06
  • 52 Week High
  • VRTX $519.88
  • AON $412.97
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 44.78
  • AON 55.81
  • Support Level
  • VRTX $471.50
  • AON $393.85
  • Resistance Level
  • VRTX $513.98
  • AON $402.49
  • Average True Range (ATR)
  • VRTX 12.35
  • AON 6.20
  • MACD
  • VRTX -4.12
  • AON -0.23
  • Stochastic Oscillator
  • VRTX 27.48
  • AON 76.52

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About AON Aon plc (Ireland)

Aon is a leading global provider of insurance and reinsurance brokerage and human resources solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in over 120 countries.

Share on Social Networks: